Shell Asset Management Co. Acquires 701 Shares of Insulet Co. (NASDAQ:PODD)

Shell Asset Management Co. grew its position in shares of Insulet Co. (NASDAQ:PODDFree Report) by 32.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,886 shares of the medical instruments supplier’s stock after acquiring an additional 701 shares during the quarter. Shell Asset Management Co.’s holdings in Insulet were worth $460,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PODD. Moneta Group Investment Advisors LLC boosted its holdings in shares of Insulet by 101,333.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock valued at $382,818,000 after buying an additional 1,299,095 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Insulet by 55.4% in the 1st quarter. Geode Capital Management LLC now owns 1,486,725 shares of the medical instruments supplier’s stock valued at $473,166,000 after buying an additional 529,926 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock valued at $452,016,000 after buying an additional 474,545 shares during the last quarter. Norges Bank acquired a new stake in shares of Insulet in the 4th quarter valued at approximately $105,275,000. Finally, D1 Capital Partners L.P. boosted its holdings in shares of Insulet by 63.5% in the 2nd quarter. D1 Capital Partners L.P. now owns 723,238 shares of the medical instruments supplier’s stock valued at $208,538,000 after buying an additional 281,000 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Morgan Stanley upgraded Insulet from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $185.00 to $234.00 in a research note on Monday, December 4th. JPMorgan Chase & Co. cut their price target on Insulet from $325.00 to $162.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 17th. SVB Leerink initiated coverage on Insulet in a research note on Monday, October 16th. They set an “outperform” rating and a $184.00 price target on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Insulet in a research note on Monday, October 16th. Finally, Piper Sandler cut their price target on Insulet from $325.00 to $250.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $250.40.

Read Our Latest Stock Report on Insulet

Insulet Stock Performance

Shares of PODD opened at $192.55 on Monday. The business’s fifty day simple moving average is $202.87 and its two-hundred day simple moving average is $188.00. The company has a current ratio of 3.26, a quick ratio of 2.35 and a debt-to-equity ratio of 2.26. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The company has a market cap of $13.45 billion, a price-to-earnings ratio of 112.60, a P/E/G ratio of 2.13 and a beta of 1.05.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

See Also

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.